MedPath
HSA Approval

NEMLUVIO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 30MG

SIN17207P

NEMLUVIO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 30MG

NEMLUVIO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 30MG

March 17, 2025

GALDERMA SINGAPORE PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGALDERMA SINGAPORE PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

SUBCUTANEOUS

Medical Information

D11AH12

Manufacturer Information

GALDERMA SINGAPORE PRIVATE LIMITED

Vetter Pharma-Fertigung GmbH & Co. KG

Active Ingredients

Nemolizumab

30mg

Nemolizumab

Documents

Package Inserts

Nemluvio Powder and Solvent for Solution for Injection PI.pdf

Approved: March 17, 2025

Patient Information Leaflets

Nemluvio Powder and Solvent for Solution for Injection PIL.pdf

Approved: March 17, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NEMLUVIO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 30MG - HSA Approval | MedPath